It is not clear whether new Alzheimer’s drugs will make a difference at a population level, say researchers

Medical Xpress August 6, 2024
University of Cambridge

Cambridge researchers have cast doubt on whether new amyloid immunotherapy drugs will have the desired effect of significantly reducing the impact of Alzheimer’s disease.

Writing in the journal Alzheimer’s & Dementia, the team from Cambridge Public Health argues that substantial challenges including the risk-benefit ratio, limited eligibility and high cost of roll-out will limit any benefits of these treatments.

Alzheimer’s disease is often quoted as causing 70% of the 55 million cases of dementia worldwide, though the definition of what constitutes the disease is hotly debated. One characteristic of Alzheimer’s is the build-up of clusters of misfolded proteins, one of these being a form of amyloid, leading to plaques in the brain. The cascade hypothesis, a dominant theory in the...

Today's Sponsors

Today's Sponsor